Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Next Previous
Search
Trial Profile

Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoblituzumab (Primary) ; FT-516 (Primary) ; Interleukin-2 (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 12 Apr 2022 Status changed from recruiting to completed.
  • 12 Apr 2021 Status changed from not yet recruiting to recruiting.
  • 19 Feb 2021 Planned initiation date changed from 15 Jan 2021 to 1 Apr 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top